Tango Therapeutics (TNGX) R&D president sells 27,000 shares after exercising options

Rhea-AI Filing Summary

Tango Therapeutics, Inc. President of R&D Crystal Adam reported an exercise-and-sale transaction in company stock. On June 1, 2026, she exercised 27,000 stock options at $5.20 per share and sold 27,000 common shares in open-market trades at weighted average prices of $22.25 and $23.06 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, she directly holds 142,743 shares of common stock and 341,040 stock options.

Insights

Equity compensation and insider-trading analyst

Planned, routine exercise-and-sell with insider retaining a sizable position.

Crystal Adam, President of R&D at Tango Therapeutics, exercised 27,000 options at $5.20 and sold 27,000 common shares on June 1, 2026. The filing shows two sale tranches at weighted average prices of $22.2520 and $23.0558 per share.

The footnotes state these trades occurred under a Rule 10b5-1 trading plan adopted on October 27, 2025, indicating they were pre-scheduled rather than opportunistic. After the transactions, she still holds 142,743 common shares and 341,040 options, so this represents a partial monetization, not an exit.

Because the activity is compensation-related and carried out under a pre-arranged plan, it generally carries limited signaling value compared with unscheduled open-market buying or selling. There is no remaining derivative position from this specific option grant; subsequent filings may detail future exercises from other awards if and when they occur.

Insider Trade Summary 10b5-1

Net Seller: 27,000 shares ($617,571)

Net Sell 4 txns

Insider Crystal Adam

Role President, R&D

Sold 27,000 shs ($618K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	27,000	$0.00	--
Exercise	Common Stock	27,000	$5.20	$140K
Sale	Common Stock	6,140	$22.252	$137K
Sale	Common Stock	20,860	$23.0558	$481K

Holdings After Transaction: Stock Option (Right to Buy) — 341,040 shares (Direct, null); Common Stock — 142,743 shares (Direct, null)

Footnotes (1)

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $21.58 to $22.57 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.60 to $23.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Key Figures

Shares sold: 27,000 shares Sale prices (weighted avg): $22.2520 and $23.0558 per share Options exercised: 27,000 options +5 more

8 metrics

Shares sold 27,000 shares Open-market sales of common stock on June 1, 2026

Sale prices (weighted avg) $22.2520 and $23.0558 per share Weighted average sale prices for two trade tranches

Options exercised 27,000 options Stock options converted to common stock on June 1, 2026

Option exercise price $5.20 per share Exercise price of stock option grant

Common shares held 142,743 shares Direct common stock ownership after transactions

Options remaining 341,040 options Total stock options following the derivative transaction

Net share change -27,000 shares NetBuySellShares from transaction summary (net-sell)

Option expiration March 1, 2033 Expiration date of the exercised stock option grant

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), weighted average sales price, derivative exercise/conversion, +2 more

6 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"Security title listed as Stock Option (Right to Buy) with underlying Common Stock."

weighted average sales price financial

"Represents the weighted average sales price per share. The shares sold at prices ranging from $21.58 to $22.57 per share."

derivative exercise/conversion financial

"Transaction action described as derivative exercise/conversion for the option transaction."

exercise or conversion of derivative security financial

"Transaction code description states Exercise or conversion of derivative security."

vest and become exercisable financial

"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crystal Adam

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		M(1)		27,000	A	$5.2	142,743	D
Common Stock	06/01/2026		S(1)		6,140	D	$22.252(2)	136,603	D
Common Stock	06/01/2026		S(1)		20,860	D	$23.0558(3)	115,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.2	06/01/2026		M(1)			27,000	(4)	03/01/2033	Common Stock	27,000	$0	341,040	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $21.58 to $22.57 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.60 to $23.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

	/s/ Julie Fogarty, as attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Tango Therapeutics (TNGX) report for Crystal Adam?

Tango Therapeutics reported that President of R&D Crystal Adam exercised 27,000 stock options and sold 27,000 common shares on June 1, 2026. The sales were open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted in October 2025.

At what prices did Crystal Adam sell Tango Therapeutics (TNGX) shares?

Crystal Adam sold Tango Therapeutics common shares at weighted average prices of $22.2520 and $23.0558 per share. Footnotes note actual trades occurred in ranges from $21.58 to $23.42 per share, with full breakdowns available upon regulatory or shareholder request.

How many Tango Therapeutics (TNGX) shares does Crystal Adam hold after this Form 4?

Following the June 1, 2026 transactions, Crystal Adam directly holds 142,743 shares of Tango Therapeutics common stock. The Form 4 also reports 341,040 stock options remaining, providing additional potential future equity exposure beyond her current share ownership.

What stock options did Crystal Adam exercise at Tango Therapeutics (TNGX)?

She exercised 27,000 stock options with an exercise price of $5.20 per share, converting them into common stock. A footnote explains the option vests over four years, with 25% vesting on February 27, 2024 and the remainder in 36 equal monthly installments thereafter.

Was Crystal Adam’s Tango Therapeutics (TNGX) share sale part of a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state that these transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Such plans pre-schedule trades, reducing the significance of trade timing as a signal of management’s short-term outlook.

What is the net effect of Crystal Adam’s June 1, 2026 Tango Therapeutics (TNGX) trades?

The filing shows an exercise of 27,000 options and open-market sales totaling 27,000 shares, resulting in a net sale of 27,000 shares. Despite this, she retains 142,743 common shares plus 341,040 options, indicating continued substantial exposure to Tango Therapeutics equity.